Treat to target approach for asthma

Area of Science:

• Pulmonology
• Clinical Medicine
• Pharmacology

Background:

• Asthma mortality is high, with many deaths preventable by adhering to guidelines, indicating a need for improved implementation and novel strategies.
• Current asthma guidelines paradoxically recommend symptomatic treatment over addressing the underlying chronic inflammation.
• The
• Treat to Target
• (TTT) approach, successful in other chronic diseases, offers a framework for more proactive asthma management.

Discussion:

• Applying TTT to asthma involves setting primary targets like clinical remission, symptom elimination, reduced exacerbation risk, prevention of airway remodeling, and normalized lung function.
• The proposed TTT algorithm for chronic asthma advocates for replacing short-acting beta2-agonists (SABA) with "Anti-Inflammatory Reliever Therapy" (AIR).
• AIR involves using inhaled corticosteroids (ICS) combined with either SABA or formoterol for reliever medication across all asthma severity levels.

Key Insights:

• Early initiation of ICS/SABA or ICS/formoterol as AIR is recommended for individuals with mild, recent-onset asthma.
• This strategy shifts from purely symptomatic relief to targeting the inflammatory mechanisms of asthma.
• The TTT approach provides a structured method to optimize asthma control and potentially reduce mortality.

Outlook:

• Further research and clinical trials are needed to validate the efficacy and long-term outcomes of the TTT approach in asthma.
• Widespread adoption of TTT could lead to significant reductions in asthma exacerbations, hospitalizations, and mortality.
• This paradigm shift in asthma management holds promise for improving patient quality of life and achieving better disease control.